September 11, 2014
Barry Hochfelder of Supply & Demand Chain Executive magazine has recently taken a look at the changing pharma landscape which is shaping industry strategy and transforming the global life science supply network.
In his piece, he interviewed TraceLink's Brian Daleiden, VP of Marketing, to understand the impacts of the new Drug Supply Chain Security Act (DSCSA) on the industry. Barry and Brian discussed the mission of protecting patient safety by establishing greater visibility and traceability across the supply chain from manufacturer to dispenser. The discussion then led into a look at the IT, operations and trade network challenges that implementation of DSCSA creates for manufacturers, wholesale distributors and other supply chain participants given the scope of the law and the diversity of the network.
You can read the article here.